ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment. Ionizing radiation (IR)-induced DNA damage repair (DDR) pathway activation leads to the inhibition of immune microenvironment, thus impairing the antitumor effect of radioimmunotherapy. However, it is unclear whether inhibition of the DDR pathway can enhance the effect of radioimmunotherapy. In this study, we aim to explore the role of DDR inhibitor AZD6738 on the combination of radiotherapy and immune checkpoint inhibitors (ICIs) in HCC. Methods C57BL/6 mouse subcutaneous tumor model was used to evaluate the ability of different treatment regimens in tumor growth control and tumor recurrence inhibition. Effects of each treatment regimen on the alterations of immunophenotypes including the quantification, activation, proliferating ability, exhaustion marker expression, and memory status were assessed by flow cytometry. Results AZD6738 further increased radiotherapy-stimulated CD8 + T cell infiltration and activation and reverted the immunosuppressive effect of radiation on the number of Tregs in mice xenografts. Moreover, compared with radioimmunotherapy (radiotherapy plus anti-PD-L1 (Programmed death ligand 1)), the addition of AZD6738 boosted the infiltration, increased cell proliferation, enhanced interferon (IFN)-γ production ability of TIL (tumor-infiltrating lymphocyte) CD8 + T cells, and caused a decreasing trend in the number of TIL Tregs and exhausted T cells in mice xenografts. Thus, the tumor immune microenvironment was significantly improved. Meanwhile, triple therapy (AZD6738 plus radiotherapy plus anti-PD-L1) also induced a better immunophenotype than radioimmunotherapy in mice spleens. As a consequence, triple therapy displayed greater benefit in antitumor efficacy and mice survival than radioimmunotherapy. Mechanism study revealed that the synergistic antitumor effect of AZD6738 with radioimmunotherapy relied on the activation of cyclic GMP–AMP synthase /stimulator of interferon genes (cGAS/STING) signaling pathway. Furthermore, triple therapy led to stronger immunologic memory and lasting antitumor immunity than radioimmunotherapy, thus preventing tumor recurrence in mouse models. Conclusions Our findings indicate that AZD6738 might be a potential synergistic treatment for radioimmunotherapy to control the proliferation of HCC cells, prolong survival, and prevent tumor recurrence in patients with HCC by improving the immune microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, ATR inhibitors appear to offset the ability of RT to drive PD-L1 upregulation (Vendetti et al., 2018) and hence synergize with RT and ICIs in the control of mouse hepatocellular carcinomas established in immunocompetent hosts (Sheng et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sheng et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Based on preliminary translational observations, our work raised the possibility that AZD6738 might be a potential synergistic modality for radioimmunotherapy in HCC. Remark-edly, this study provides a basis for future clinical human studies into the treatment of HCC.”
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“In summary, compared with radioimmunotherapy, triple therapy can further reduce the coexpression of CD8 + T cell exhaustion markers in mice xenograft tumors and spleens.”
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · cited 1×
“7 8 There are increasing substantial preclinical studies showing that radiotherapy combined with ICIs improve the control rate and reduce the recurrence rate of multiple types of cancers, including HCC. 9 Therefore, it appears that the combination of radiotherapy and ICIs may become a promising…”
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · cited 1×
“11 14 However, other than simulative effect, radiation also has suppressive effect on the tumor environment.”
Cited by
Items 201–241 of 241
Zhang, J., Yu, B., Chu, H., Hu, B., Chen, L., Yang, W., Zhang, R., & Zhao, W. (2020) · doi:10.21203/rs.3.rs-111299/v1
“In general, the stronger the immune cell invasion in the tumor microenvironment, the more able to inhibit tumor progression [39-42].”
BackgroundVendetti, F. P., Clump, D. A., Schamus-Haynes, S., diMayorca, M. S., Islam, N. M., Chang, J., Beumer, J. H., & Bakkenist, C. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.11.487886
“More recently, preclinical studies have also shown that ATRi can potentiate anti-tumor immune responses, but the underlying mechanisms are not well-understood (17, 19, 25-28).”
BackgroundDuda, D. G., & Hauth, F. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_18
Vendetti, F. P., Clump, D. A., Schamus-Haynes, S., diMayorca, M. S., Islam, N. M., Chang, J., Beumer, J. H., & Bakkenist, C. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4093294
Breast cancer prognostic signature associated with DNA damage response-related genesPreprint
Xu, J., Wang, L., Wang, J., Yue, J., Feng, R., Wang, S., Zhang, X., Li, H., Ren, G., & Cheng, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2175420/v1
Self-citationSingh, N., Agrawal, S., & Narayanan, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0531
DNA Repair Mechanisms as a New Target in Head and Neck Cancer
Harrington, K. J., Hak, C. C. W., Rullan, A., & Patin, E. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-23175-9_3
Wang, Y. (2023) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/1991
Tashakori, N., Kolour, S. S. P., Ghafouri, K., Ahmed, S. I., Kahrizi, M. S., Gerami, R., Altafi, M., & Nazari, A. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155289
Guo, Y., Wang, J., Benedict, B., Chen, Y., van Gemert, F. P. A., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829569
Self-citationGuo, Y., Wang, J., Benedict, B., Chen, Y., van Gemert, F. P. A., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829560
Self-citationTherapeutic Targeting of ATR in Cancer
Haciefendi, A., & Eskiler, G. G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_318
Biological and therapeutic aspects of combination of radiotherapy with selected immune modulators
Gottwald, A., Tang, Y., Fietkau, R., Gaipl, U. S., & Jost, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00027-8
Tian, L., Wang, Y., Guan, J., Zhang, L., & Fan, J. (2025) · Genes · doi:10.3390/genes16030346
“Research has indicated that immune checkpoint inhibitors (ICIs) can bring positive outcomes for advanced-stage hepatocellular carcinoma patients [9].”
Zhang, X., Wu, G., Li, J., Yin, L., Gao, M., Han, X., Zhao, X., & Xu, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-04050-5
“Based on previous study [18], we screened out 223 BM-related genes (BMRGs) (shown in Supplementary Table S1).”
Germino, E., Zettlitz, K. A., Watkins, T., Chen, B. Y., Placa, D. L., Salazar, F. B., Chean, J., Li, S., McGee, H. M., Williams, T. M., et al. (2025) · npj Imaging · doi:10.1038/s44303-025-00128-5
Lee, C.-Y., Schlom, J., Hodge, J. W., & Fabian, K. P. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04260-4
Guo, Y., Wang, J., Benedict, B., Yang, C., van Gemert, F., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829572
Self-citationGuo, Y., Wang, J., Benedict, B., Yang, C., van Gemert, F., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829566
Self-citationTriple terapia en cáncer: inhibidores de reparación de ADN, radioterapia e inmunoterapia
Gómez Estévez, P. (2023) · Deposito de Investigacion Universidad de Sevilla (University of Seville)
Bukhari, A. B., Wuest, M., Wuest, F. R., & Gamper, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.10.710900
Impact des acides nucléiques cytosoliques sur l’immunité antitumorale dans un modèle de glioblastome
Marines, J. (2021) · theses.fr (ABES) · doi:10.70675/305c0c98z32d3z4938z98dbz2a0580de4d04
Leveraging the replication stress response to optimize hepatocarcinoma therapy
Fang, J. (2024) · theses.fr (ABES) · doi:10.70675/e829496azb11ez4563zb5c8z74b7e8e8ff61
Kawahara, M., Fujino, H., Fujii, Y., Ono, A., Kawaoka, T., Hayes, C. N., Tsuge, M., Nakagiri, T., Arihiro, K., & Oka, S. (2026) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-026-02329-w
“Although targeted therapies such as Ataxia telangiectasia mutated and Rad3-related Checkpoint kinase 1 (ATR/CHK1) and Enhancer of zeste homolog 2 (EZH2) inhibitors are under investigation [ 25], they are not yet clinically established.”
Huang, L., Yang, Y., Dai, L., Zhou, J., Shao, J., & Qian, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-52778-z
“Another study also reported that AZD6738 treatment increased innate immune cell infiltration through activation of the cGAS/STING pathway 34 .”
ATR kinase inhibitors induce mitochondrial fission in CD8 + T cells and impair immune memory in vivoPreprint
Vendetti, F. P., Sclafani, C. R., Zhang, Y., Pandya, P., Mowery, Y. M., Kim, S. H., Cumberland, R. L., Ganakammal, S. R., Conrads, T. P., Calderon, M. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727628
Fan, H., Liu, Y., Wu, G., Rao, M., Zhang, J., Zhu, P., & Zhang, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-55609-3
Fu, Z., Zhang, Y., Wang, Z., Li, Z., & Du, S. (2026) · Precision Radiation Oncology · doi:10.1002/pro6.70057
Tarfouss, J., Senar, O. A., Stosic, K., Verset, L., Bouchart, C., Navez, J., Laethem, J. V., Demols, A., & Arsenijevic, T. (2026) · Cancers · doi:10.3390/cancers18132134
“For example, inhibition of ATR amplifies the radiation-induced inflammatory tumor microenvironment and DNA damage, forcing irradiated cells to enter mitosis with unrepaired DSBs [174,175].”
Dias, A. B., Ohradanova‐Repic, A., Dupanovic, A., Fischer, P., Horvat, F., Appel, L.-M., Bragato, N., Gebetsberger, L., Barna, S., Widder, J., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111699
Recent Progress in Targeting Kinases Involved in the DNA Damage Response for the Treatment of Cancer
Buckley-Benbow, L., Rout, A. M., Fielding, A. B., Parsons, J. L., Gadd, M. S., & Allinson, S. L. (2026) · Targets · doi:10.3390/targets4030024
“…ceralasertib’s potential in combination therapy was provided in reports of its synergy with radioimmunotherapy (radiotherapy and anti-PD-L1) against hepatocellular carcinoma mice xenografts [66] and with both photon and proton radiation in various cancer cell lines and a TNBC xenograft model [67].”
Sun, Y., Zhong, J., Sun, H., Parr, G., Lukacs, E., Slade, D., Zhou, Y., Ren, X., Kirk, D., Kmieciak, A., et al. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00458-3
Self-citationDorotenko, A. R., Shustova, M. S., Vlasenko, A. V., Kiselev, A. S., Blokhina, M., Moiseyenko, V. M., Zhukova, L., Stroyakovskiy, D., Breder, V. V., Феденко, А. А., et al. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2026.2.203748
Guo, L., Kong, L., Guan, S., Xu, L., Wang, J., Zhong, D., & Zhang, L. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04496-8
“Recent studies suggest that cell cycle-specific DNA damage in tumor cells can activate the cGAS-STING pathway, initiating anti-tumor innate immunity [22, 24, 28 ].”
Self-citationBhakuni, R., Lee, J. H., Goff, P. H., Jones, D., Nguyen, L., Lin, R., Newell, E. W., Garman, K. A., Hall, E. T., Gilad, O., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01688-4
“Ofnote,thetriple combination(ATRi + radiation + ICI) approach has reliably been associated with enhanced adaptive immunologic memory and improved survival in murine models 19,22,25,98 .”
Wen, Y., Cheng, N., Zhou, S., Zhu, H., & Ge, Q. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1927654
“Additionally, DDR inhibition exemplified by ATR blockade synergizes with RT to augment ICD and neoantigen release via cGAS-STING pathway activation (Sheng et al., 2020; Patin et al., 2022).”
Lopez, J. S., Im, S., Postel-Vinay, S. C., Campone, M., El-Khoueiry, A. B., Abida, W. M., Arkenau, H., Lee, K., Rha, S. Y., Jodrell, D. I., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03601-z
Chen, T., Zhang, J., Sun, J., Zhang, H., Huang, D., & Ye, H. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5944
“Firstly, traditional chemotherapy and radiotherapy can induce DNA damage to mediate the activation of this pathway in HCC (92,105).”
Self-citationKarthikeyan, M. C., Viswanathan, Y., Dinakaran, P., Manivannan, S., & Arockiam, A. J. V. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02789-8
DNA Repair Pathways as Determinants of PARP Inhibitor Resistance and Therapeutic Targets in Cancer
Lavudi, K., Renjith, M. S., Psvv, C., Kokkanti, R. R., Pandey, P. K., & Ponneganti, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219814
Metadata
- Authors
- Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., Zhang, W., Sun, J., & Cao, C.
- Affiliations
- Nanfang Hospital (CN)
- Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
- Department of Stomatology, No 2 Hospital of Baoding, Baoding, Hebei, China
- Corresponding author
- Cao, Chuanhui
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-05
- Volume
- 8
- Issue
- 1
- Pages
- e000340
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7254123
- OpenAlex
- W3029836467
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 24 · 2025: 40 · 2024: 36 · 2023: 42 · 2022: 49 · 2021: 31 · 2020: 5
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81702390, 81903133)
- Guangzhou Science and Technology Program key projects (201906010087)
- Natural Science Foundation of Guangdong Province (2017A030310105, 2018A030313398)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- AZD6738, hepatocellular carcinoma, radioimmunotherapy, DNA repair inhibition, tumor immune microenvironment, immune checkpoint inhibitors, PD-L1 inhibitors, radiotherapy, cGAS-STING pathway, CD8+ T cells, regulatory T cells, T cell exhaustion, tumor-infiltrating lymphocytes, immunological memory, combination therapy, tumor recurrence
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Drug Synergism, Female, Carcinoma, Hepatocellular, Humans, Indoles, Liver Neoplasms, Morpholines, Pyrimidines, Sulfonamides, Sulfoxides, Lymphocytes, Tumor-Infiltrating, Radioimmunotherapy, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.